{"disease":{"id":"glioblastoma-idh-isocitrate-dehydrogenase-wildtype","name":"glioblastoma idh isocitrate dehydrogenase wildtype"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05879367","title":"Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":66,"lead_sponsor_name":"Orbus Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04677049","title":"Study of Niacin in Glioblastoma","phase":"PHASE1, PHASE2","overall_status":"SUSPENDED","enrollment_count":59,"lead_sponsor_name":"AHS Cancer Control Alberta","has_results":false},{"nct_id":"NCT05375318","title":"BIOhabitats: Biological Validation of Vascular Habitats Within Astrocytoma Grade 4 at Molecular, Cellular, and Histopathological Levels","phase":"","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Juan M Garcia-Gomez","has_results":false},{"nct_id":"NCT07416188","title":"Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT07386002","title":"The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"T-MAXIMUM Pharmaceutical Inc","has_results":false},{"nct_id":"NCT07520214","title":"Clinical Study on the Safety and Immunogenicity of Specific Cancer Vaccines in Preventing Recurrence of Glioblastoma","phase":"EARLY_PHASE1","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":9,"lead_sponsor_name":"Beijing Neurosurgical Institute","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}